Changes in the costs of antihypertensive medications in a developing country -: A study in Mexico comparing 1990 and 1996

被引:9
作者
Calvo-Vargas, CG [1 ]
Carrillo, JZP [1 ]
Páez, FG [1 ]
Reyes, SF [1 ]
机构
[1] Univ Guadalajara, New Civil Hosp Guadalajara, Cardiovasc Res Unit, Guadalajara 44430, Jalisco, Mexico
关键词
high blood pressure; cost of antihypertensive medications; developing countries;
D O I
10.1016/S0895-7061(97)00459-7
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
In developing countries, the cost of antihypertensive medications is one of the principal limiting factors when trying to treat patients with high blood pressure. To determine the changes in cost (in US dollars) of these medications and in the percentage of the minimum wage needed to purchase them, two cost studies (1990 and 1996) done in Mexico were compared. The yearly cost of a treatment with hydrochlorothiazide was US $13.80 in 1990; in 1996 it was US $10.92. Both figures represent 1.1% of the minimum wage that was in effect at the time. Propranolol hydrochloride cost US $50.52 for a year's treatment in 1990, and US $66.12 for the same in 1996. These figures represented, respectively, 4.2% and 6.7% of the minimum wage of 1990 and 1996. The annual cost for nifedipine was US $176.76 in 1990 (14.7% of the minimum wage) and US $242.16 in 1996 (24.8% of the minimum wage). The yearly cost of enalapril was US $233.04 in 1990 and US $433.20 in 1996; these costs represented, respectively, 19.4% and 44.2% of the minimum wage. The comparison of these two cost studies (1990 and 1996) shows why Mexico's population is finding it more difficult to purchase antihypertensive medications. Higher costs and reduced purchasing power seem to be the two principal factors causing this. This is probably affecting the population's health, as it is more difficult to control high blood pressure without proper treatment. (C) 1998 American Journal of Hypertension, Ltd.
引用
收藏
页码:487 / 493
页数:7
相关论文
共 22 条
  • [1] *ADV BOARD INT HEA, 1992, ADV BOARD INT HEART
  • [2] BLACK HR, 1993, HYPERTENSION, V21, P335
  • [3] Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS) - A randomized controlled trial
    Borhani, NO
    Mercuri, M
    Borhani, PA
    Buckalew, VM
    CanossaTerris, M
    Carr, AA
    Kappagoda, T
    Rocco, MV
    Schnaper, HW
    Sowers, JR
    Bond, MG
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (10): : 785 - 791
  • [4] CALVOVARGAS C, 1994, MED INTERN MEXICO, V10, P212
  • [5] *DIR GEN EP ENC NA, 1993, SIST NAC ENC SAL
  • [6] REPORT OF THE TASK-FORCE ON THE AVAILABILITY OF CARDIOVASCULAR DRUGS TO THE MEDICALLY INDIGENT
    DUSTAN, HP
    CAPLAN, LR
    CURRY, CL
    DELEON, AC
    DOUGLAS, FL
    FRISHMAN, W
    HILL, MN
    WASHINGTON, RL
    STEIGERWALT, S
    SHULMAN, NB
    TAUBERT, KA
    CHAMPAGNE, B
    GROOM, A
    [J]. CIRCULATION, 1992, 85 (02) : 849 - 860
  • [7] LONG-TERM COST-EFFECTIVENESS OF VARIOUS INITIAL MONOTHERAPIES FOR MILD TO MODERATE HYPERTENSION
    EDELSON, JT
    WEINSTEIN, MC
    TOSTESON, ANA
    WILLIAMS, L
    LEE, TH
    GOLDMAN, L
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (03): : 407 - 413
  • [8] CAN PHYSICIAN EDUCATION LOWER THE COST OF PRESCRIPTION DRUGS - A PROSPECTIVE, CONTROLLED TRIAL
    FRAZIER, LM
    BROWN, JT
    DIVINE, GW
    FLEMING, GR
    PHILIPS, NM
    SIEGAL, WC
    KHAYRALLAH, MA
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (02) : 116 - 121
  • [9] CONSEQUENCES OF THE NORTH-AMERICAN FREE-TRADE AGREEMENT FOR HEALTH-SERVICES - A PERSPECTIVE FROM MEXICO
    FRENK, J
    GOMEZDANTES, O
    CRUZ, C
    CHACON, F
    HERNANDEZ, P
    FREEMAN, P
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 1994, 84 (10) : 1591 - 1597
  • [10] GIFFORD RW, 1993, ARCH INTERN MED, V153, P154